Imugene’s (ASX:IMU) HER-Vaxx and CF33 platforms to feature at ASCO - Kalkine Media

Highlights

• Imugene will present its HER-Vaxx and CF33 technologies at the ASCO Gastrointestinal Cancers Symposium
• The event is scheduled to be held from 19-21 January 2023 in San Francisco
• Over 4,000 scientific figures, oncologists, clinical researchers, academics, and medical practitioners participate in the event every year

In the latest announcement, ASX-listed clinical-stage immuno-oncology company Imugene Limited (ASX:IMU) revealed that its HER-Vaxx and CF33 technologies will be featured at the forthcoming ASCO Gastrointestinal Cancers Symposium. The event is scheduled to be held from 19-21 January 2023 in San Francisco.

At the 20th annual international event, the most recent developments and breakthroughs in the field of gastrointestinal oncology will be showcased. More than 4,000 scientific figures, clinical researchers, academics, oncologists, and medical practitioners from around the world participate in the event every year.

Multiple sessions at ASCO

Imugene will be featured during the Oral Abstract Session at the event with the abstract title ‘HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma— Overall survival analysis’.

Also, Imugene will be presenting during the 'Trials in Progress Poster Session' under the abstract title, 'nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment.' 

In a ‘Poster Session’ at the event, IMU will be featured under two abstract titles, namely - ‘Development of a novel chimeric oncolytic viral platform, CF33 and its derivatives, for peritoneal directed CF33-OV treatment of gastric cancer peritoneal carcinomatosis’ and ‘Ex vivo oncolytic and immune activity of CF33-hNIS-antiPDL1 against fresh peritoneal cells from patients with gastric cancer with and without peritoneal metastases’.

IMU shares were trading at AU$0.165 each at 11:42 AM AEDT on 19 December 2022.